IOVA Stock Risk & Deep Value Analysis
Iovance Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IOVA Stock
We analyzed Iovance Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IOVA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IOVA Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Upcoming Risk Events
- 📅
Slower-than-expected AMTAGVI commercial uptake
- 📅
Clinical trial failures for pipeline candidates
- 📅
Increased competition in the cell therapy space or novel immunotherapies
- 📅
Need for additional capital raise leading to significant dilution
Unlock IOVA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Iovance Biotherapeutics Inc (IOVA) Do?
Market Cap
$1.63B
Sector
Healthcare
Industry
Biotechnology
Employees
838
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Visit Iovance Biotherapeutics Inc WebsiteInvestment Thesis
Iovance is a high-risk, high-reward opportunity positioned to revolutionize solid tumor treatment with its first-in-class TIL therapy, AMTAGVI. Early commercial success, improving manufacturing margins, and a robust pipeline expansion with lifileucel for sarcomas provide a compelling path to significant market share and potential 10x growth, despite current unprofitability and leadership's insider selling.
Is IOVA Stock Undervalued?
Unlock the full AI analysis for IOVA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IOVA Price Targets & Strategy
12-Month Target
$9.00
Bull Case
$16.00
Bear Case
$3.00
Valuation Basis
Based on a 3.5x forward Price/Sales multiple on projected FY2027 revenue of $1.0B.
Entry Strategy
Consider dollar-cost averaging between $3.50-$4.50, capitalizing on current undervaluation relative to analyst consensus and recent support levels.
Exit Strategy
Take partial profits at $9.00 (median analyst target) and $16.00 (high analyst target); stop loss at $3.00 if commercial execution falters or cash burn accelerates significantly.
Portfolio Allocation
7-15% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is IOVA Financially Healthy?
Valuation
P/E Ratio
-3.54
Profitability
Gross Margin
50.00%
Revenue Growth
61.00%
EPS
$-0.18
Balance Sheet
Cash & Equivalents
$303.00M
Other
Beta (Volatility)
0.68
Does IOVA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily driven by regulatory hurdles and the highly specialized, complex manufacturing required for TIL therapy, creating significant barriers to entry for competitors. Continued innovation and successful commercialization will reinforce this moat.
Moat Erosion Risks
- •Emergence of competing TIL therapies or other highly effective immunotherapies
- •Challenges in scaling manufacturing, leading to supply constraints or cost inefficiencies
- •High cost of therapy limiting broader adoption or reimbursement challenges
IOVA Competitive Moat Analysis
Sign up to see competitive advantages
IOVA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Focus is primarily on institutional and analyst views, less on broad retail sentiment currently.
Institutional Sentiment
Positive - Majority Buy consensus from analysts, with recent upgrades/PT raises post-Q4 earnings. Significant institutional buying observed (e.g., Invenomic adding 2.25M shares, 149 institutions adding in Q4 2025).
Insider Activity (Form 4)
All transactions were sells in the last 90 days: Frederick G. Vogt (Interim CEO) sold 26,755 shares ($122.54k) on 2026-03-05; Raj K. Puri (Chief Regulatory Officer) sold 18,360 shares ($84.09k) on 2026-03-05; Igor Bilinsky (COO) sold 16,628 shares ($76.16k) on 2026-03-05 and 6,903 shares ($26.16k) on 2026-03-02; Finckenstein Friedrich Graf (CMO) sold 7,122 shares ($26.99k) on 2026-03-02; Daniel Gordon Kirby (CCO) sold 34,165 shares ($129.14k) on 2026-02-24.
Options Flow
Normal options activity - No specific unusual options activity data provided.
Earnings Intelligence
Next Earnings
Expected late April / early May 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Recent Q4 2025 revenue beat suggests improving commercial execution, but it's too early to establish a consistent historical reaction pattern given the early commercial stage.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No specific direct TIL competitor in provided data)
Market Share Trend
Gaining - As a first-in-class approved TIL therapy, Iovance is establishing initial market share in advanced melanoma.
Valuation vs Peers
Trading at a significant discount to projected peak sales potential relative to established cell therapy companies, reflecting high execution risk inherent in early commercialization of a novel platform.
Competitive Advantages
- •First-in-class FDA approved Tumor Infiltrating Lymphocyte (TIL) therapy
- •Proprietary autologous manufacturing process expertise
- •Deep clinical pipeline targeting multiple solid tumor indications with TILs
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IOVA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (expected)
- •Continued AMTAGVI commercial ramp-up and sales growth
- •Initiation of registrational trial for lifileucel in soft tissue sarcomas (Q2 2026)
Medium-Term (6-18 months)
- •Further clinical data readouts for lifileucel in new indications (e.g., cervical cancer)
- •Manufacturing scale-up and further gross margin improvement
- •Potential strategic partnerships for broader market access
Long-Term (18+ months)
- •AMTAGVI achieving blockbuster status across multiple solid tumor indications
- •Establishment of TIL therapy as a standard of care for refractory solid tumors
- •Pipeline diversification beyond lifileucel
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IOVA?
- ✓
Acceleration in AMTAGVI revenue growth rates and expanding patient access
- ✓
Positive clinical trial data for lifileucel in new indications beyond melanoma
- ✓
Significant reduction in cash burn and clear pathway to profitability
- ✓
Shift in insider activity towards buying, signaling renewed leadership confidence
Bull Case Analysis
See what could go right with Premium
Competing with IOVA
See how Iovance Biotherapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Iovance Biotherapeutics Inc IOVA | $1.6B | 6.5 | -3.5 | $263.5M | 0.0% | 61.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Iovance Biotherapeutics Inc (IOVA)?
As of March 24, 2026, Iovance Biotherapeutics Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Iovance Biotherapeutics Inc?
Iovance Biotherapeutics Inc's market capitalization is approximately $1.6B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Iovance Biotherapeutics Inc use?
IOVA is the ticker symbol for Iovance Biotherapeutics Inc. The company trades on the NGM.
What is the risk level for IOVA stock?
Our analysis rates Iovance Biotherapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IOVA?
Iovance Biotherapeutics Inc currently has a price-to-earnings (P/E) ratio of -3.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Iovance Biotherapeutics Inc's revenue growing?
Iovance Biotherapeutics Inc has reported revenue growth of 61.0%. The company is showing strong top-line momentum.
Is IOVA stock profitable?
Iovance Biotherapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the IOVA DVR analysis updated?
Our AI-powered analysis of Iovance Biotherapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IOVA (Iovance Biotherapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.